SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2024-11-01 (dailysabah.com)
EU slaps Israeli generic drugmaker Teva with $500M antitrust fine
The European Commission announced Thursday it had imposed an antitrust fine exceeding 460 million euros ($500 million) on Israeli generic drugmaker Teva...
Read more
2024-10-31 (netnoticias.mx)
EU penalizes Teva for abuse of power, receives historic fine
500 million dollars for protecting patents and violating competition rules
Read more
2024-10-31 (lavoz.com.ar)
EU fines Teva 460 million euros for trying to protect patent for sclerosis medicine
EU fines Teva 460 million euros for trying to protect patent for sclerosis medicine
Read more
2024-10-31 (ilsole24ore.com)
EU fine of almost half a billion euros to the pharmaceutical giant Teva
The accusation is of having hindered competition for its flagship drug for the treatment of multiple sclerosis, Copaxone, by abusing the patent system and delegitimizing the product of rival Synthon
Read more
(aboutpharma.com)
Teva fined 462 million by the European Commission for obstructing a competing drug against multiple sclerosis
Abuse of dominant position: Teva's role in hindering the arrival of the glatiramer acetate generic on the European market recognized
Read more